

***Amendments***

It is respectfully requested that the following amendments to the specification and claims be entered in advance of substantive examination.

***In the Claims:***

Please add the following new claims:

67. (New) The adjuvant composition of claim 1 wherein the co-lipid is a neutral lipid.

68. (New) The adjuvant composition of claim 1 wherein the co-lipid is a phosphatidylethanolamine.

B' 69. (New) The adjuvant composition of claim 68 wherein the phosphatidylethanolamine is selected from the group consisting of DOPE, DPyPE, and DMPE.

70. (New) The adjuvant composition of claim 69 wherein the phosphatidylethanolamine is DOPE.

71. (New) The adjuvant of claim 69 wherein the phosphatidylethanolamine is DPyPE.

72. (New) The adjuvant of claim 1 wherein the GAP-DMORIE and the co-lipid are in molar ratio of from about 9:1 to about 1:9.

73. (New) The adjuvant of claim 1 wherein the GAP-DMORIE and the co-lipid are in molar ratio of from about 4:1 to about 1:4.

74. (New) The adjuvant of claim 1 wherein the GAP-DMORIE and the co-lipid are in molar ratio of from about 2:1 to about 1:2.

75. (New) The adjuvant of claim 1 wherein the GAP-DMORIE and the co-lipid are in molar ratio of about 1:1.

B<sup>1</sup>  
76. (New) The adjuvant of claim 71 wherein the GAP-DMORIE and DPyPE are in molar ratio of from about 2:1 to about 1:2.

77. (New) The adjuvant of claim 71 wherein the GAP-DMORIE and DPyPE are in molar ratio of about 1:1.

78. (New) An immunogenic composition comprising:

(a) an immunogen, and

(b) an adjuvant composition comprising GAP-DMORIE and one or more co-lipids;

wherein said immunogen is one or more antigenic polypeptides, immunogenic polypeptides or polysaccharides.

79. (New) A method for immunizing a vertebrate comprising:

administering into a tissue or cavity of said vertebrate an immunogenic composition comprising

- (a) one or more antigenic polypeptides, immunogenic polypeptides or polysaccharides in an amount sufficient to generate an immune response to said one or more antigenic polypeptides, immunogenic polypeptides or polysaccharides, and
- (b) an adjuvant composition comprising GAP-DMORIE.

80. (New) A method for providing a mammal a prophylactic or therapeutic

treatment associated with a bacterial infection comprising:

administering to the mammal an immunogenic composition comprising

- (a) one or more antigenic polypeptides, immunogenic polypeptides or polysaccharides associated with the bacterial infection in an amount sufficient to generate an immune response to said one or more antigenic polypeptides, immunogenic polypeptides or polysaccharides, and
- (b) an adjuvant composition comprising GAP-DMORIE and one or more co-lipids.

81. (New) A method for providing a mammal a prophylactic or therapeutic

treatment associated with a viral infection comprising:

administering to the mammal an immunogenic composition comprising

- (a) one or more antigenic polypeptides, immunogenic polypeptides or polysaccharides associated with the viral infection in an amount sufficient to generate an

immune response to said one or more antigenic polypeptides, immunogenic polypeptides or polysaccharides, and

- (b) an adjuvant composition comprising GAP-DMORIE and one or more co-lipids.

82. (New) A method for providing a mammal a prophylactic or therapeutic treatment associated with an abnormal growth of a cell population comprising:

administering to the mammal an immunogenic composition comprising

(a) one or more antigenic polypeptides, immunogenic polypeptides or polysaccharides associated with the abnormal growth of the cell population in an amount sufficient to generate an immune response to said one or more antigenic polypeptides, immunogenic polypeptides or polysaccharides, and

- (b) an adjuvant composition comprising GAP-DMORIE and one or more co-lipids.

83. (New) A pharmaceutical kit comprising:

(a) a container holding one or more antigenic polypeptides, immunogenic polypeptides or polysaccharides, and

(b) an adjuvant composition comprising GAP-DMORIE and one or more co-lipids;

wherein said one or more antigenic polypeptides, immunogenic polypeptides or polysaccharides is provided in a prophylactically or therapeutically effective amount to treat a vertebrate.

---